An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors
Condition(s) studied
Investigational drug(s) / intervention(s)
RPTR-1-201: RPTR-1-201
PD-1 / PD-L1 monoclonal antibody: PD-1/PD-L1 monoclonal antibody
Study summary
This is an early phase trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of RPTR-1-201 in adults with advanced solid tumors. The trial includes dose escalation and dose expansion parts and will evaluate RPTR-1-201 as monotherapy and in combination with an anti-PD-1 monoclonal antibody.
Eligibility
Primary outcome measure(s)
- Number of participants with dose-limiting toxicities and treatment-emergent adverse events. — From first dose through 30 days after last dose of trial treatment.
Number of participants experiencing dose-limiting toxicities and treatment-emergent adverse events, including events considered related to RPTR-1-201, graded according to CTCAE v5.0. - Objective Response Rate (ORR) per RECIST v1.1 — From first dose until end of treatment or documented disease progression, whichever occurs first (assessed up to 24 months).
Proportion of participants with a best overall response of complete response or partial response per RECIST v1.1, as assessed by the investigator.
Trial sites (12)
| Facility | City | Region | Status |
|---|---|---|---|
| START Midwest | Grand Rapids | Michigan | Recruiting |
| START New York-Long Island | Lake Success | New York | Recruiting |
| START San Antonio | San Antonio | Texas | Recruiting |
| START Dublin | Dublin | Ireland | Recruiting |
| START Lisbon | Lisbon | Portugal | Recruiting |
| START Barcelona | Barcelona | Spain | Recruiting |
| START Rioja | Logroño | Spain | Recruiting |
| Clinica Universidad de Navarra - Madrid | Madrid | Spain | Recruiting |
| START Madrid-CIOCC | Madrid | Spain | Recruiting |
| START Madrid-FJD | Madrid | Spain | Recruiting |
| Clinica Universidad de Navarra - Pamplona | Pamplona | Spain | Recruiting |
| INCLIVA Instituto de Investigación Sanitaria VLC | Valencia | Spain | Recruiting |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07293754 on ClinicalTrials.gov ↗ ← All trials in the USA